The GlyHealth-IBD tests were able to predict IBD disease severity with ROC sensitivity and specificity scores in the range 0.88 – 0.92 (a perfect score is 1.0) compared to hsCRP and albumin with a combined score of 0.57 (0.5 is the lowest possible score). The GlyHealth-IBD studies and method are described in our paper ‘Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease’ submitted to Nature Comms. 

The GlyHealth-IBD tests were able to predict IBD disease severity with ROC sensitivity and specificity scores in the range 0.88 – 0.92 (a perfect score is 1.0) compared to hsCRP and albumin with a combined score of 0.57 (0.5 is the lowest possible score). The GlyHealth-IBD studies and method are described in our paper ‘Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease’ submitted to Nature Comms. 

Our exploratory studies demonstrated that our GlyHealth-Index test for measurement of general chronic inflammation is superior to other commonly used biomarkers to detect and monitor chronic levels of inflammation in patients.

GlyHealth Index (GHI) and high-sensitivity C-Reactive Protein (hsCRP) were tested using a group of over 400 people which included individuals with inflammatory bowel disease (IBD) and control samples. Receiver operating characteristic (ROC) analyses of the cohort show that the GHI and clinical markers were assessed to predict inflammation.

Our exploratory studies demonstrated that our GlyHealth-Index test for measurement of general chronic inflammation is superior to other commonly used biomarkers to detect and monitor chronic levels of inflammation in patients.

GlyHealth Index (GHI) and high-sensitivity C-Reactive Protein (hsCRP) were tested using a group of over 400 people which included individuals with inflammatory bowel disease (IBD) and control samples. Receiver operating characteristic (ROC) analyses of the cohort show that the GHI and clinical markers were assessed to predict inflammation.

GHI marker depicted an area under the curve (AUC) of 0.76 in the ROC analyses shown in Panel A. hsCRP marker gave an AUC of 0.60 for prediction of inflammation.

Our exploratory studies demonstrated that glycan biomarkers used in Glyhealth-IBD-Escalate (GIE) outperform the clinical biomarkers (albumin and hs-CRP) for prediction of disease escalation in IBD patients.

GlyHealth-IBD glycomics biomarkers and clinical markers such as albumin and high-sensitivity C-Reactive Protein  (hsCRP) were tested using a cohort consisting of 422 individuals with inflammatory bowel disease (IBD) as well as control samples. Both glycomics markers and clinical markers were assessed separately to evaluate the capability of prediction of disease progression/treatment escalation.

In some cases, clinicians, and patients are taken by surprise by the severity of a covid-19 infection. We speculate that chronic levels of inflammation, previously un-detected using conventional technology, may establish which individuals are likely to have a poorer health outcome upon infection. By knowing this patient, and clinicians are better informed as to how to manage their general health and to escalate treatment sooner, in order to prevent debilitating health outcomes now and in the future.